AEON Biopharma (AEON) Stock: Buy, Sell, or Hold?
AEON - AEON Biopharma, Inc.
$0.24
-0.01 (-5.46%)
▼
5d:
-23.36%
30d:
-14.76%
90d:
-66.63%
WAIT
LOW Confidence
Analysis Updated: Sep 4, 2026 12:00 AM ET
Earnings: Aug 11, 2026
0d
Get Alerted When AEON Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: AEON is down 23.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: AEON is down 23.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: AEON is currently trading at $0.24, which is considered fair relative to its 30-day fair value range of $0.23 to $0.29.
Technical Outlook: Technically, AEON is in a strong downtrend. Immediate support is located at $0.19, while resistance sits at $0.33. Short-term momentum is weak, with the stock down 5.5% recently.
Market Sentiment: AEON scores 30/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $1.43 (+495.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, AEON is in a strong downtrend. Immediate support is located at $0.19, while resistance sits at $0.33. Short-term momentum is weak, with the stock down 5.5% recently.
Market Sentiment: AEON scores 30/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $1.43 (+495.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$0.23 -
$0.29
Company Quality Score
36/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
44.7%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (30/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.5%)
- BULLISH: Trading 495.2% below Wall St target ($1.43)
- WARNING: Composite score 36/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.23 -
$0.29
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$0.19
Resistance Level
$0.33
Current Trend
Strong Downtrend
Technical data as of
Sep 4, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.96
Wall Street Target
$1.43
(+495.2%)
Share & Embed Analysis
Last updated: September 07, 2026 2:07 AM ET
Data refreshes hourly during market hours. Next update: 3:07 AM
Data refreshes hourly during market hours. Next update: 3:07 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AEON showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 59 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$432 | 46 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 57 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 40 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$86 | 46 HOLD |
